Vaxcyte Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PCVX$67.53+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating expenses: | |||
| Research and development (including related party expenses of $0, $0 and $2,359 in 2023, 2022 and 2021, respectively) | $332,341 | $169,451 | $78,411 |
| Acquired manufacturing rights (Note 7) | 75,000 | 22,995 | - |
| General and administrative | 60,700 | 39,810 | 25,259 |
| Total operating expenses | 468,041 | 232,256 | 103,670 |
| Loss from operations | (468,041) | (232,256) | (103,670) |
| Other income (expense), net: | |||
| Interest expense | — | (2) | (7) |
| Interest income | 62,907 | 8,356 | 344 |
| Grant income | 4,765 | 1,931 | 1,585 |
| Realized gains on marketable securities | — | — | 2 |
| Loss on disposal of fixed assets | — | (44) | — |
| Foreign currency transaction (losses) gains | (1,897) | (1,470) | 1,669 |
| Total other income, net | 65,775 | 8,771 | 3,593 |
| Net loss | $(402,266) | $(223,485) | $(100,077) |
| Net loss per share, basic and diluted | $(4.14) | $(3.44) | $(1.93) |
| Weighted-average shares outstanding, basic and diluted | 97,157,690 | 64,877,988 | 51,922,108 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.